EverHint – EMA 10/30 Crossover, SMA 20/50 Crossover, EMA 10 + Price + MACD – Top 6 Buy and Top 10 Sell Signals for Nov 17, 2026
Excerpt: 16 signals (from 64 total). Healthcare leads (15). price range $10-$396. 3 with insider selling.
EMA 10/30 Crossover
Detects fresh crossovers between the 10-day exponential moving average (EMA10) and the 30-day exponential moving average (EMA30), generating both buy and sell signals. Uses two EMAs instead of EMA + SMA, making it more responsive to price changes and better suited for capturing short-to-medium term momentum shifts.
Entry Criteria:
- Buy: EMA10 crosses above EMA30
- Sell: EMA10 crosses below EMA30
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 1-4 weeks | Risk level: Medium
🟢 Buy Signals (4 of 4)
Ranked by RSI (lower RSI for buy signals = more oversold)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | CAKE | The Cheesecake Factory... | Consumer Cyclical | $111.96 | — | $5.6B |
| 2 | RARE | Ultragenyx Pharmaceuti... | Healthcare | $16.70 | — | $1.7B |
| 3 | TRGP | Targa Resources Corp. | Energy | $291.35 | — | $62.5B |
| 4 | ZIM | ZIM Integrated Shippin... | Industrials | $29.69 | — | $3.6B |
🔴 Sell Signals (5 of 53)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | AAMI | Acadian Asset Management | Financial Services | $86.97 | — | $3.1B |
| 2 | AI | C3.ai, Inc. | Technology | $9.96 | — | $1.5B |
| 3 | ANF | Abercrombie & Fitch Co. | Consumer Cyclical | $142.85 | — | $6.1B |
| 4 | AR | Antero Resources Corpo... | Energy | $36.83 | — | $11.3B |
| 5 | AX | Axos Financial, Inc. | Financial Services | $88.15 | — | $5.0B |
SMA 20/50 Crossover
Detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50). Uses two SMAs, making it more stable and less prone to false signals compared to EMA-based strategies. Well-suited for identifying medium-term trend changes with higher reliability.
Entry Criteria:
- Buy: SMA20 crosses above SMA50
- Sell: SMA20 crosses below SMA50
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh crossover: Detected on today's close
Holding period: 2-6 weeks | Risk level: Medium
🟢 Buy Signals (1 of 1)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | STNG | Scorpio Tankers Inc. | Industrials | $80.69 | — | $4.1B |
🔴 Sell Signals (5 of 5)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | CAI | Caris Life Sciences, Inc. | Healthcare | $19.94 | — | $5.7B |
| 2 | MPC | Marathon Petroleum Cor... | Energy | $395.61 | — | $107.7B |
| 3 | MTCH | Match Group, Inc. | Communication Services | $40.09 | — | $9.1B |
| 4 | OSCR | Oscar Health, Inc. | Healthcare | $29.84 | — | $7.7B |
| 5 | PSX | Phillips 66 | Energy | $256.93 | — | $100.2B |
EMA 10 + Price + MACD
Experimental strategy combining price crossing above EMA10 from below with MACD Line crossing above Signal Line from below. Both conditions must occur on the same day for a signal, providing double confirmation and higher-quality setups.
Entry Criteria:
- Buy: Price > EMA10 AND MACD line crosses above signal line
- Sell: Price < EMA10 AND MACD line crosses below signal line
- Minimum ADV: $40M (liquidity filter)
- Earnings buffer: 7 days pre/post earnings
- Fresh signal: All conditions met on today's close
Holding period: 1-3 weeks | Risk level: Medium-High
🟢 Buy Signals (1 of 1)
Ranked by RSI (lower RSI = more oversold for buy signals)
| # | Ticker | Company | Sector | Price | Insider | MCap |
|---|---|---|---|---|---|---|
| 1 | SLS | SELLAS Life Sciences G... | Healthcare | $19.15 | — | $3.9B |
Recent Headlines
SLS (SELLAS Life Sciences Group, Inc.)
- SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia Prepared Remarks Transcript
- SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/
📢 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.